Pay in 4 interest-free payments of $7.22 Learn more
Ships within 48 hours · Estimated delivery Sep 5 - Sep 10
Orforglipron: Phase 3 Data Shows Ozempic-Like Results, In Pill Form Dave Knapp Apr 17, 2025 2 min read Updated: Apr 18, 2025 Eli Lillys oral GLP-1 candidate orforglipron met all primary and secondary endpoints in a Phase 3 study of adults with type 2 diabetes, the company announced Thursday
Front Biosci (Landmark Ed)
FDA Disclosure This information is for educational purposes only and is not intended to diagnose, treat, cure, or prevent any disease
The translation of the discovery into therapies has transformed diabetes management, beginning with the approval of exenatide, the first GLP-1 receptor agonist (GLP-1RA), in 2005 by the U.S
This history proves you are not looking for an easy way out
Some providers prescribe metformin as a bridge during GLP-1 discontinuation, particularly for people with insulin resistance or prediabetes
